leading cause of non-traumatic lower extremity amputations in the United States, and approximately
14-24% of patients with diabetes who develop a foot ulcer will require an
amputation. Foot ulceration precedes
85% of diabetes-related amputations.
The gold standard for Diabetic Foot Ulcer treatment includes debridement of the wound, management of any infection, revascularization procedures when indicated, and off-loading of the ulcer.
Currently, the market is mainly dominated by
off-label generic drugs such as analgesics and anti-infectives,
around 78% of the current market is captured by these two classes of drugs.
There is only one drug,
Regranex (Becaplermin), which the FDA has approved.
Regranex gel uses a Platelet-derived growth factor (PDGF) for the Diabetic Neuropathic Ulcer treatment formulated to act as a first-line treatment following effective ulcer care. The US FDA had approved the biologics license application of Becaplermin (OMJ Pharmaceuticals, Inc
7
Injection Pen Market Research Report conducts a deep estimation of the present state of the Injection Pen Industry with the definition, classification, and market scope. The data included in the report has been generated by consulting industry leaders and taking inputs from them. The topmost subdivisions of the market have been emphasized and these divisions have been presented by giving statistics on their current state by the end of the forecast horizon.
Injection Pen Market Insight:
Injection pen market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 64.15 billion by 2027 growing at a CAGR of 6.87% in the above-mentioned forecast period. The growth of the injection pen market is due to increasing occurrence of diseases such as diabetes and arthritis will fuel the growth of the market.